CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

Sanxing Guo, Sibylle Loibl, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Carsten Denkert

Cancer Research and Treatment. 2020;52(3):689-696. Published online 2020 February 4 DOI: https://doi.org/10.4143/crt.2019.497

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

Sanxing Guo, Sibylle Loibl, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Carsten Denkert

Cancer Research and Treatment. 2020;52(3):689-696

Link1

Link2 Link3

Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer

Mary Kay Barton

CA: A Cancer Journal for Clinicians. 2014;64(3):155-156

Link1

CD24 Polymorphisms Cannot Predict Pathologic Complete Response to Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy in Breast Cancer

Xin Zhou

Clinical Breast Cancer. 2014;14(2):e33-e40

Link1 Link2

Pathologic Complete Response in Breast Cancer Patients Receiving Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy: Evaluating the Effect of Race/Ethnicity

W.M. Sikov

Yearbook of Oncology. 2011;2011:23-26

Link1 Link2

Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy

Min Jung Kim, Eun-Kyung Kim, Seho Park, Hee Jung Moon, Seung Kim, Byeong-Woo Park

Acta Radiologica. 2015;56(9):1069-1077

Link1 Link2 Link3

The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy

Alex Farr, Myriam Stolz, Lukas Baumann, Zsuzsanna Bago-Horvath, Elisabeth Oppolzer, Georg Pfeiler, Michael Seifert, Christian F. Singer

The Breast. 2017;33:153-158

Link1 Link2

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

Mathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, Anna S. Berghoff, Regina Promberger, Matthias Preusser, Peter Dubsky, Florian Fitzal, Michael Gnant, Guenther G. Steger, Ansgar Weltermann, Christoph C. Zielinski, Otto Zach, Rupert Bartsch

Cancer Chemotherapy and Pharmacology. 2014;73(4):771-778

Link1

Link2 Link3

Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy

Filippo Montemurro, Serena Di Cosimo

The Breast. 2014;23(5):690-691

Link1 Link2

GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy

Jason K. Wasserman, Phillip A. Williams, Shahidul Islam, Susan J. Robertson

Pathology - Research and Practice. 2016;212(6):539-544

Link1 Link2

Neoadjuvant chemotherapy carboplatin – taxane response in locally advanced triple negative breast cancer patients in relation to molecular biomarkers

L.M. Sad, S. Younis, M. Abd El Hak

Annals of Oncology. 2016;27:vi92

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.